Photo by mykjohnson from unsplash
To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin‐N; Biocon Biologics Ltd., Bangalore, India) and US‐licensed Humulin® N (Humulin‐N; Eli Lilly and Company,… Click to show full abstract
To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar Insulin N (Biocon's Insulin‐N; Biocon Biologics Ltd., Bangalore, India) and US‐licensed Humulin® N (Humulin‐N; Eli Lilly and Company, Indianapolis, IN, USA) in healthy subjects.
Keywords:
pharmacodynamic equivalence;
biosimilar insulin;
equivalence;
pharmacokinetic pharmacodynamic;
biocon;
insulin
Journal Title: Diabetes
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!